Arrowhead Pharmaceuticals Inc (ARWR) — Capital Reinvestment Ratio

Latest as of September 2025: 0.37x

Arrowhead Pharmaceuticals Inc (ARWR) has a Capital Reinvestment Ratio of 0.37x as of September 2025, meaning it reinvests 0% of its operating cash flow ($20.49 Million) in capital expenditures ($7.49 Million). See how leveraged is Arrowhead Pharmaceuticals Inc's balance sheet to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.37x
Capex / Operating Cash Flow

Operating Cash Flow

$20.49 Million
USD

Capital Expenditures

$7.49 Million
USD

Data as of

Sep 2025
Most recent filing

Arrowhead Pharmaceuticals Inc Capital Reinvestment Ratio (2019–2025)

This chart tracks Arrowhead Pharmaceuticals Inc's Capital Reinvestment Ratio across 3 annual periods. Check ARWR cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for Arrowhead Pharmaceuticals Inc (2019–2025)

Year-by-year Capital Reinvestment Ratio for Arrowhead Pharmaceuticals Inc from 2019 to 2025. For live market cap and broader valuation context, see Arrowhead Pharmaceuticals Inc stock valuation.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2025 0.13x $179.55 Million $22.67 Million ▼ -8.3%
2021 0.14x $171.22 Million $23.57 Million ▲ +98.4%
2019 0.07x $173.03 Million $12.00 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow